The purpose of this study was t o characterize the stimulus that activates the 5-lipoxygenase pathway in human peripheral monocytes (PM) during the process of contact activation. Incubation of PM, but not of polymorphonuclear leukocytes (PMN), in contact-activated, recalcified plasma induced a time-dependent release of leukotrienes (LT). The presence of plateletcr was required for the generation of cysteinyl-LT, but LTB4 formation also proceeded in their absence, although t o a lesser extent. Plasmin, presumably generated via the intrinsic fibrinolytic pathway, was liable for the Ilipoxygenase stimulation during contact activation inasmuch as (1) the 5-lipoxygenase pathway in PM was stimulated by contact-activated, recalcified, autologous or homologous plasma, but not by factor XII-deficient or prekallikrein-deficient plasma; (2) lysine analogs such as W-acetyl-L-lysine, 6-aminohexanoic acid (6-AHA), or trans-4-(aminomethyl)cyclohexane-l-carboxylic acid (t-AMCA), which inhibit plasmin(ogen) binding t o PM plasmin(ogen) binding sites, concentration-dependently reduced the cysteinyl-LT release; (3) plasminogen activators such as urokinase or streptokinase concentration-dependently enhanced N PREVIOUS STUDIES, we have shown that contactinduced clotting of human whole blood in vitro is not only accompanied by generation of cyclooxygenase-derived thromboxane (TX) Az, but also by formation of 5-lipoxygenase-derived leukotrienes (LT).'" A time-dependent release of chemotactic LTB4,45 as well as vasoconstrictory and edemogenic cysteinyl-LT: has been demonstrated, and the identity of the immunoreactive material has been confirmed by reverse-phase high-performance liquid chromatography (RP-HPLC) and in the case of cysteinyl-LT additionally by bioassay."3 Activation of the 5-lipoxygenase pathway by the process of blood coagulation is not restricted to in vitro conditions, since it was also detectable in blood permitted to clot in clamped autologous umbilical vein segments, as well as in fresh thrombus specimens obtained from patients with acute deep vein thrombosis of the lower limb.' Thus, intravascular 5-lipoxygenase activation is likely to occur during thrombotic events in humans.
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The stimulation of the 5-lipoxygenase pathway was found to be practically independent from endogenously generated thrombin, because thrombin inhibitors such as recombinant hirudin and D-Phe-Pro-Arg-CHzC1 blocked the thrombin-mediated TXBz release, but did not affect the cysteinyl-LT f~rmation.~ Likewise, incubation of autologous blood cells carrying the 5-lipoxygenase enzyme, such as polymorphonuclear leukocytes (PMN) or peripheral monocytes (PM) in Hanks' balanced salt solution (HBSS) in the presence of human a-thrombin, did not trigger any detectable 5-lipoxygenase a~tivation.~
By supplementation experiments, we recently gained evidence that the 5-lipoxygenase activated in contact-activated human whole blood is selectively stimulated in PM, but not in PMN. ' The cellular allocation of the 5-lipoxygenase stimulated permitted us to reduce the system to the crucial components involved. Thus, in our present study, PM have I the cysteinyl-LT release up t o 10 and 1,000 IUlmL, respectively, while higher concentrations were less effective leading to bell-shaped concentration-response curves; (4) plasmin inhibitors such as aprotinin or a2-antiplasmin concentration-dependently inhibited the cysteinyl-LT release; and (5) preincubation of plasma with monoclonal antibodies directed against plasminogen and capable of preventing plasminogen activation blocked the contact-mediated 5 4 -poxygenase stimulation. Moreover, incubation of PM with plasmin, but not with plasma kallikrein, in Hanks' balanced salt solution (HBSS)-bovine serum albumin (BSA) 0.4% t r i g gered a concentration-dependent release of LTB4 up t o 0.1 caseinolytic units (CU)/mL, with higher concentrations being less effective. By contrast, release of cyclooxygenase metabolites such as thromboxane (TX) B2 and prostaglandin (PG) E2 was not stimulated by plasmin, indicating specificity for the 5-lipoxygenase pathway. With plasmin as a hitherto unknown stimulus of the 5-lipoxygenase pathway in PM, a novel link between contact activation and inflammation has been established. 0 1994 by The American Society of Hematology.
been incubated in contact-activated, recalcified, autologous platelet-rich (PRP) or platelet-poor (PPP) plasma. Regarding the characterization of the stimulus leading to contact-mediated 5-lipoxygenase activation in PM, we considered contact activation-related processes interacting with the cell membrane of PM as potential trigger mechanisms.
collected by free-flow technique from the antecubital vein of medication-free, apparently healthy, male volunteers (age, 21 to 33 years) with normal differential blood cell counts.
Monocytes were isolated on Percoll gradients basically as previously de~cribed.~.' In brief, mononuclear cells were prepared from EDTA (5 mmol/l)-anticoagulated blood by centrifugation (300g, 20 minutes, 20°C) against 61% Percoll-NaC1 (vol/vol). After washing once with NaCl 150 mmol/L, mononuclear cells were resuspended in PPP anticoagulated with 5 mmoUL EDTA. This cell suspension was centrifuged (800g, 40 minutes, 4°C) through discontinuous EDTA (5 mmol/L)-PPP-Percoll gradients of 25% and 39% Percoll (voUvol), respectively. PM collected in a band of 294.0% purity at the 25%/39% interphase. The cells were washed twice in HBSSbovine serum albumin (BSA) 0.4% (wt/vol). Two percent to 6% lymphocytes were found. Platelet satellism, ie, platelets associated with the PM membrane, was less than seven platelets per 100 monocytes. Cell purity was generaliy checked by phase-contrast microscopy and after staining with Turk's solution or Wright stain. Viability of all cell preparations was more than 98% as judged by Trypan blue exclusion. PM were further characterized by staining for anaphtyl-acetate esterase (>95% positive staining). Furthermore, transmission and scanning electron microscopy have been used for the identification of PM and for the determination of platelet satellism.
PMN were prepared from heparin-anticoagulated blood (20 U/ mL) by centrifugation (300g, 20 minutes, 20°C) through two-step Percoll-NaCI (150 mmoVL) gradients of 61% and 75% Percoll (VOV vol). Mononuclear cells and PMN collected atop the 61 % and 75% Percoll phase, respectively. After washing twice in NaCl 150 mmoU L, remaining erythrocytes were removed by hypotonic lysis (NaC1 0.2% [wt/vol] for 1 minute). PMN were washed once more and purity was more than 98% with less than 2% lymphocytes.
Washed platelets were prepared as basically described by Marcus.' However, the platelets were washed in Ca2+-and Mg*+-free HBSS, and were finally resuspended in HBSS-BSA 0.4%. PRP was prepared from blood anticoagulated with trisodium citrate 3.8% (wthol, 1 v01 trisodium citrate +9 v01 blood) (310g, 20 minutes, 20°C). Except for the experiments with various platelet concentrations, PRP was generally adjusted with PPP to 3 X 10' plateletslmL. PPP for cell incubations and dilution of PRP was prepared from PRP by centrifuging plasma twice (2,500g, 20 minutes, 4°C). PPP for Percoll gradients was prepared from EDTA (5 mmoUL)-anticoagulated blood.
Experimental protocol. When PM or PMN were incubated in recalcified plasma, 100 pL of HBSS-BSA 0.4% containing the desired cell number were pipetted into borosilicate glass tubes, and 900 pL of autologous PRP or PPP were added. Plasma was recalcified with 0.3 moUL CaC12 solution, resulting in a final concentration of 1.1 mol/L of free Caz+ ions as determined by a Ca2+-sensitive electrode (Orion Research, Cambridge, MA). These samples were allowed to clot up to 120 minutes at 37°C as indicated. In experiments with factor XII-deficient or prekallikrein-deficient plasma, homologous plasma had been used. In experiments with monoclonal antibodies (TC 4PG) able to prevent plasminogen activation," plasma samples were preincubated with 8 pmoUL TC 4PG for 15 minutes before recalcification and contact activation. Lysine analogs such as 6-aminohexanoic acid (6-AHA), trans-.l-(aminomethy1)cyclohexane-I-carboxylic acid (t-AMCA), or W-acetyl-L-lysine, and plasminogen activators such as urokinase or streptokinase were dissolved in NaCl 150 mmoVL and were added in a volume of 20 pL. Similarly, the plasmin inhibitors aprotinin and a,-antiplasmin were dissolved in NaCl 150 mmol/L and were added in volumes of 20 and l00 pL, respectively.
In experiments with HBSS-BSA 0.4%, PM were incubated in polystyrene tubes for 60 minutes at 37°C in 500 pL. Plasmin dissolved in HBSS and kallikrein dissolved in NaCl 150 mmoVL were added in a volume of 20 pL. In control experiments, PM in HBSS-BSA 0.4% were stimulated for 20 minutes with 1 pmol/L ionophore A 23 187 dissolved in dimethyl sulfoxide. Experimental controls always received the appropriate solvents.
At the time points indicated, incubations were stopped by rapid centrifugation at 4°C and the supernatants were used for further analysis.
Analytical procedures. Serum or HBSS-BSA levels of cysteinyl-LT, LTB,, TXB2, or prostaglandin (PG) E2 were determined radioimmunologically as previously de~cribed."~.~ The validity of the assays for LT had been established by RP-HPLC.".* Before analysis of cysteinyl-LT, proteins were precipitated by addition of 3 v01 of precooled acetone. After storage at -2O"C, centrifugation and evaporation of the supernatants under reduced pressure, the residues were resuspended in Tris-HC1 50 mmoVL, pH 7.4, and finally used for the radioimmunological determination of cysteinyl-LT contents. The anticysteinyl-LT antiplasma recognizes mainly LTC,, but exhibits 78% and 49% relative cross-reaction with LTD, and LTE,, respectively, whereas other eicosanoids do not interfere with the assay. Cysteinyl-LT were calculated in terms of LTC,-like material, since upon RP-HPLC, immunoreactivity coeluted mainly with the retention time of synthetic LTC,. According to the manufacturer (Amersham, Braunschweig, Germany) the highest relative cross-reaction of the anti-LTB, antiplasma (0.3%) is found with 20-OH-LTB4. In buffer, the detection limits of the assays were 32 fmoUtube for LTC,. 20 fmoUtube for LTB4, 28 fmoUtube for TXB2 and 24 fmoUtube for PGE2. All radioimmunological determinations were performed on the background of appropriate blank samples, which in the case of PRP were obtained by immediate centrifugation. Standard curves were always prepared in blank samples, which were run through the whole procedure.
For RP-HPLC, sample proteins were precipitated and the residues resuspended in Tris-HCI 50 mmol/L, pH 7.4, were further purified by Cl, Sep-Pak (Waters, Milford, MA) extraction as described elsehere.^.^ RP-HPLC was performed using a C,, Nucleosil column (Macherey-Nagel, Duren, Germany) (250 X 4 mm; particle size, S pm) protected by a precolumn at a flow rate of 1 mllrnin. For cysteinyl-LT, a solvent system consisting of methanollwatedacetic acid (65:35:0.1 by volume, pH 5.6) containing 1 mmoUL EDTA'-x was used, while that for LTB, consisted of methanoUwater/acetic acid (68:32:0.01 by volume, pH 5.5). UV absorbance was scanned at 280 nm, and all samples contained PGBz as an internal standard. Eluates were evaporated, resuspended in radioimmunoassay buffer, and tested in the appropriate radioimmunoassay.
Stutisrics. Values are expressed as the mean t SEM. Statistical analysis was performed using Student's t-test for paired or unpaired data as applicable. In cases of multigroup comparisons, t statistics were corrected by the Bonferroni method or the Newman-Keul's test was applied. Differences were considered significant when P was less than .05. ICso values calculated by the standard least-square method are presented as geometric means and 95% confidence limits. cysteinyl-LT into the serum samples was observed upon incubation of 15 X lo5 PM/mL. In these samples, the cysteinyl-LT formation was significantly higher at 30 and 60 minutes as compared with incubations with the lower PM number (n = 6 each, P < .05, Fig lA) , although it was not triplicated, as one might have expected.
RESULTS

Generation
In contrast, incubation of PM in Ca2+-PPP at cell densities of 5 or 15 X 105/mL did not induce any detectable cysteinyl-LT release during the 120-minute incubation period ( Fig  1B) .
Similar to cysteinyl-LT formation, a time-dependent release of immunoreactive LTB4 was found when PM (5 or 15 X 105/mL) were incubated in Ca2+-PRP (Fig 2A) . At 5 X lo5 PM/mL, LTB, serum levels significantly increased from 125 2 19 pg/mL at 15 minutes to 465 2 47 pg/mL at A 1600 1 60 minutes and further to 694 5 73 pg/mL at 120 minutes (n = 5 each, P < .005). The higher cell number of PM (15 X 105/mL) resulted in a much larger LTB4 release relative to the lower cell number of PM (5 X 105/mL) when compared with the cysteinyl-LT production shown in Fig 1A. The increased release of LTB4 with the higher cell number of PM (15 X l@/mL) was significant at any time point of the incubation period (P < .Ol). The difference in LTB4 formation between the two PM cell densities was highest at 15 minutes with a factor of 3.25, and steadily decreased up to 120 minutes, reaching a factor of 2.12 ( Fig 2A) .
In contrast to Fig lB, where we could not detect any cysteinyl-LT release when PM (5 or 15 X 105/mL) were incubated in Ca2+-PPP, these samples did contain immunoreactive LTB,, although at a clearly reduced level ( Fig 2B) . With 5 X lo5 PWmL, immunoreactive LTB4 serum levels were 128 2 43 pg/mL and 477 ;t 73 pg/mL at 30 and 120 minutes, respectively (n = 5 each). At 60 and 120 minutes, the LTB, release into serum was significantly higher ( P <
.05) with 15 X lo5 PWmL as compared with 5 X 10' PM/ mL ( Fig 2B) . Incubation of PM 5 or 15 X 105/mL in HBSS-BSA 0.4% for the same length of time as in the experiments with Ca2+-plasmas did not result in any detectable cysteinyl-LT or LTB, formation (data not shown).
When PMN 5 or 15 X 106/mL were incubated up to 120 minutes at 37°C in either Ca2'-PRP, Ca2+-PPP, or HBSS-BSA 0.4%, neither any cysteinyl-LT nor LTB, formation could be detected (data not shown).
The lack of a detectable cysteinyl-LT release in the absence of platelets, ie, in contact-activated Ca2+-PPP samples containing PM, while considerable amounts of LTB4 were formed at the same time, hinted to a potential transcellular biosynthesis of cysteinyl-LT under these circumstances. Indeed, when a fixed number of PM (15 X 105/mL) were incubated for 60 minutes in autologous, contact-activated Ca*'-PRP containing various concentrations of platelets, the cysteinyl-LT release was clearly dependent on the platelet number (Fig 3A) . At a platelet concentration of 107/mL, equivalent to a 30-fold dilution of the usual platelet number of 3 X 108/mL, release of immunoreactive cysteinyl-LT was no longer detectable, ie, there was a more than 87% reduction (Fig 3A) . Similarly, incubation of various concentrations of PM in autologous, contact-activated Ca2+-PRP containing a fixed number of platelets (3 X 108/mL) demonstrated the dependency on the PM number (Fig 3B) . However, the slope of this curve is not as steep as that for the platelets. A 30-fold dilution of the PM number from 15 X 10' to 0.5 X lo5/ mL led only to a 56.4% 5 9.5% (n = 4) reduction in cysteinyl-LT release (Fig 3B) . In the absence of PM, no cysteinyl-LT could be detected (data not shown). rum from CaZ+-PRP containing 15 X lo5 PM/mL allowed to clot for 60 minutes contained immunoreactive material coeluting with the retention times of synthetic LTC,, LTD,, and LTE,. LTC, represented the largest portion, but also considerable amounts of LTD, and LTE, could be detected (Fig 4A) . Such serum samples also contained immunoreactive material that coeluted in a single peak with the retention time of LTB, (Fig 4B) . Likewise, in samples derived from Ca2'-PPP containing 15 X lo5 PWmL and incubated for 60 minutes, immunoreactive LTB4 comigrated in a single peak with the retention time of synthetic LTBJ (Fig 4C) . Dependence on contact activation. Clear evidence for the necessity of contact activation was obtained in experiments with prekallikrein-deficient or factor XII-deficient plasma incubated under contact activation conditions. Incubation of PM (1 5 X 105/mL) in contact-activated, autologous or homologous Ca2'-PPP for 60 minutes induced release of practically identical amounts of LTB4 into the serum samples (Fig 5) . In contrast, incubation of PM in either 100% (vel/ vol) prekallikrein-deficient or factor XII-deficient Ca2'-plasma under otherwise identical conditions was not accompanied by any detectable release of LTB, (<g8 pg/mL, n = 4 each, P < .005). When 50% (vol/vol) of the autologous Ca2'-PPP was replaced by either recalcified prekallikreindeficient or factor XII-deficient plasma, a moderate but significant (P < .005) inhibition of the LTB, release was observed ( Fig 5) . Both deficiency plasmas had no direct effect on the monocyte 5-lipoxygenase activity, because stimulation of PM with ionophore A23187 (1 pmol/L) for 20 minutes in either Ca2+-plasma triggered generation of identical amounts of LTB, as compared with autologous plasma (data not shown).
Effects of lysine analogs. To evaluate the possible contribution of plasmin to the contact activation-related stimulation of the 5-lipoxygenase pathway in PM, the effects of various lysine analogs on the contact-mediated cysteinyl-LT production were investigated. All of the compounds tested Results are the mean * SEM of four experiments each; nd, not detectable, t98 pglmL.
were effective inhibitors of cysteinyl-LT formation when 5 X lo5 PWmL were incubated for 60 minutes in Ca2+-PRP (Fig 6) . The weakest inhibitor was JP-acetyl-L-lysine (IC5,,. 2.23 mmol/L; range, 1.99 to 2.50 mmol/L; n = 4) while t-AMCA was the most potent compound (ICs0, 55 prnom; range, 43 to 69 pmol/L; n = 5). As expected, 6-AHA had an intermediate potency (IC%, 604 pmoVL; range, 395 to 922 pmol/L; n = 4) (Fig 6) . The highest concentrations of the lysine analogs used did not inhibit cysteinyl-LT release when PM (5 X 105/mL) incubated in HBSS-BSA 0.4% were stimulated with 1 pmol/L ionophore A 23187 for 20 minutes (data not shown).
The most potent lysine analog, t-AMCA, was used at a concentration of 100 pmol/L to test whether the LTB4 formation by PM (5 X 105/mL) incubated in Caz'-PPP for 60 minutes would be inhibited as well. Under these conditions, LTB, release into the serum samples was significantly reduced by 69.1% 2 3.8% (n = 3, P < .001; 100% value, 295 t 56 pg/mL).
Effects of plasminogen activators. Further evidence for a potential role of plasmin in the contact-mediated S-lipoxygenase activation came from experiments with plasminogen activators such as urokinase and streptokinase. Indeed, urokinase led to a concentration-dependent stimulation of cysteinyl-LT release into the serum samples, with a maximum effect at approximately 10 IU/mL (Fig 7A) . Beyond that concentration, cysteinyl-LT serum levels decreased again, resulting in a bell-shaped concentration response curve in the range between approximately 3 and 100 IU/mL, while at a concentration of 300 IU/mL no stimulatory activity could be detected (Fig 7A) . was used as a stimulus, no activation of the cysteinyl-LT production was observed between 0.1 and 30 IU/mL (data not shown). However, at streptokinase concentrations between 300 and 3,000 IU/mL, similar to the urokinase experiments, a bell-shaped concentration-response curve was observed, with a maximum at approximately 1,000 IU/mL ( Fig  7B) . Neither urokinase 10 IU/mL nor streptokinase 1,000 IU/mL triggered any release of LTB4 or cysteinyl-LT from 5 X lo5 PM/mL incubated in HBSS-BSA 0.4% for 60 minutes (data not shown).
Effects of plasmin inhibitors. As shown in Fig 8A, aprotinin concentration-dependently reduced the serum levels of cysteinyl-LT (ICs0, 316 KIU/mL; range, 208 to 481 KIU/ mL; n = 5). Similarly, exogenous a2-antiplasmin as highly specific plasmin inhibitor concentration-dependently inhibited the contact activation-mediated 5-lipoxygenase stimulation (ICs0, 566 nmol/L; range, 473 to 678 nmovL; n = 5) (Fig 8B) . On the other hand, both compounds had no effect on the ionophore A 23 187 (1 pmol/L)-stimulated cysteinyl-LT release from 5 X lo5 PWmL incubated in HBSS-BSA 0.4% for 20 minutes (data not shown).
The specific plasmin inhibitor cy,-antiplasmin was also used with PM 5 X 105/mL incubated for 60 minutes in Ca2+-PPP. Under these conditions, 1 pmol/L of a2-antiplasmin significantly reduced the LTB4 release by 78.4% 2 5.5% (n = 3, P < .001; 100% value, 295 2 56 pg/mL).
Effects of monoclonal antiplasminogen antibodies. In our final approach regarding the role of plasmin under these experimental conditions, we tested the effects of monoclonal antibodies (TC 4PG) on the release of cysteinyl-LT into serum samples from contact-activated Ca2+-PRP containing 5 X IO5 PM/mL (Fig 9A) . After 60 minutes, control samples contained considerable amounts of cysteinyl-LT (496 ? 32 pg/mL, n = 4), while in the presence of TC 4PG (8 pmoV L), which is known to protect plasminogen from activation to plasmin," no detectable release of cysteinyl-LT could be found (<75 pg/mL, n = 4, P < .001) (Fig 9A) . Similar results were obtained with respect to LTB4 release from 15 X lo5 PM/mL incubated in contact-activated, autologous Ca2+-PPP (501 2 27 pg/mL v <98 pg/mL in TC 4PG pretreated plasma, n = 4, P < ,001) (Fig 9B) . release of immunoreactive LTB+ However, when PM were incubated in the presence of plasmin 0.001 to 1
Effects of plasmin and
.O caseinolytic units (CU)/mL, a significant (P < .01) and concentrationdependent stimulation of LTB4 release was observed, reaching a maximum of 554 ? 78 pg/mL at a plasmin activity of 0.1 caseinolytic units (CU)/mL (Fig 10A) . Beyond 0.1 CU/ mL of plasmin, LTB4 formation decreased again. At a plasmin activity of 1.0 CU/mL, LTB4 levels were significantly decreased to 101 2 22 pg/mL (n = 6, P < .01) as compared with 0.1 CU/mL (Fig 1OA) . Immunoreactive LTB4 produced by PM in HBSS-BSA 0.4% upon stimulation with 0.1 CU/mL of plasmin for 60 minutes, after RP-HPLC coeluted in a single peak with the retention time of synthetic LTB4 (data not shown).
Similar to the experiments with Caz'-PRIJ (Fig 6) , the stimulatory effect of plasmin 0.1 CU/mL on LTB4 release from PM incubated for 60 minutes in HBSS-BSA 0.4% was completely abolished by 0.1 mmol/L t-AMCA or 1 .O mmoY L 6-AHA (data not shown). At the concentrations used, both compounds had no effect on the ionophore A 23 187 (1 pmoV L)-stimulated LTB4 formation (data not shown).
In the absence of platelets, release of cysteinyl-LT from PM (5 X 105/mL) incubated in HBSS-BSA 0.4% for 60 minutes in the presence of purified plasmin was close to or below the detection limit of the assay (data not shown). However, when PM coincubated with washed platelets (3 X lO'/mL) were stimulated with plasmin 0.01, 0.1, or 1.0 CU/ mL, a concentration-dependent release of cysteinyl-LT was observed (221 ? 31 pg/mL, 524 4 42 pg/mL, and 198 2 41 pg/mL, respectively, n = 4). which roughly paralleled the concentration response curve of plasmin for LTB4 release (compare Fig IOA) .
In contrast to plasmin, human plasma kallikrein in concentrations between 0.06 and 0.5 prnoVL did not trigger any detectable release of immunoreactive LTB4 from PM 15 X 105/mL incubated in HBSS-BSA 0.4% for 60 minutes (n = 3, data not shown).
To investigate a potential stimulatory effect of plasmin on the cyclooxygenase pathway of arachidonic acid metabolism, we determined the release of the two major prostanoids generated by PM. As shown in Fig 10B, plasmin did not significantly affect the release of immunoreactive TXBz or PGE2, indicating selectivity for the 5-lipoxygenase pathway.
DISCUSSION
We have previously demonstrated that clotting of human whole blood in vitro is accompanied by LT f~rmation"~ due to activation of the monocyte 5-lipoxygenase pathway of arachidonic acid metabolism.' In extension of these studies, our present results show that the complex system of contactactivated human whole blood can be successfully reduced to the essential components, namely isolated PM as the cellular source of 5-lipoxygenase activity and recalcified, contactactivated plasma providing the trigger mechanism for 5-lipoxygenase stimulation. It was this experimental setup that permitted us to perform crucial experiments, such as those with prekallikrein-deficient or factor XII-deficient plasma. These experiments clearly indicate that contact activation, which requires the presence of either factor,"." is an absolute precondition for the stimulation of the 5-lipoxygenase pathway in PM incubated in recalcified plasma.
Contact-mediated activation of the PM 5-lipoxygenase pathway in Ca2+-PRP triggered generation of both cysteinyl-LT and LTB,, while incubation of PM in Ca2+-PPP was accompanied by detectable release of LTB, only. These findings must be regarded in light of the extensive transcellular biosynthesis of eicosanoids, particularly in blood cells." Thus, the blood cell types commonly known to harbor 5-lipoxygenase activity, such as PMN and PM, release the instable intermediate LTA,, which is efficiently converted by platelets into LTC4.'4"6 Mainly due to stabilization of the labile LT&, this process is greatly enhanced by the presence of albumin'4 and is therefore favored in a plasma milieu. LTC, formation by human platelets from LTA, depends on substrate as well as platelet c~ncentration.'~ Indeed our experiments clearly demonstrate that besides the number of PM, the platelet number is a critical determinant in our system. Apart from transcellular biosynthesis, PM themselves do possess the capacity for generation of cysteinyl-LT in the absence of which was actually observed in our control experiments with 1 pmol/L ionophore A 23187-stimulated PM. Because LTC4 release may be as low as 20% of the LTB, formation when physiologic stimuli are being used," the moderate stimulation of the 5-lipoxygenase pathway in PM by contact-activated CaZ+-PPP may have led to cysteinyl-LT serum levels well below the detection limit of the assay.
The presence of platelets was required for the generation of detectable amounts of cysteinyl-LT, but it also significantly enhanced the release of LTB,. Since platelets do not seem to convert LTA, into LTB4,I4,l6 the enhanced release of LTB, observed is due to further activation of the PM 5-lipoxygenase pathway. Similarly to cysteinyl-LT formation, this stimulatory effect was dependent on the platelet number. However, it was not due to any potential substrate feeding, since labeling of platelets with [3H]-arachidonic acid before contact activation did not lead to any ['HI-labeled LT formation upon RP-HPLC profiling." 12(S)-hydroperoxy-10-trans-5,8,14-cis-eicosatetraenoic acid (12-HPETE), which as a platelet-derived arachidonic acid metabolite has been reported to stimulate LT biosynthesis in human leukocytes,*' had no stimulatory effect in concentrations up to 10 pmoV L (unpublished results). Thus, in line with other investigators, we could not detect any metabolism of platelet intermediates by PM, nor did we find any 5-lipoxygenase activation in PM by 12-HPETE.I6
Several other studies have shown an effect of platelets on a specific activity of PM. Thus, tissue factor activity was found to be higher in platelet-enriched as compared with platelet-poor mononuclear cell preparations." Although clear evidence has been presented for a role of 12-HETE under these conditions:' its generation in our experiments" is unlikely to contribute to the stimulatory effect of platelets, since, similar to lZHPETE, up to 10 pmol/L of 12-HETE did not enhance LTB, release from PM incubated in contactactivated Ca2'-PPP (unpublished results). The presence of platelets has also been reported to enhance the rate of cholesterol esterification, as well as the cholesteryl ester accumulation in PM and U937 cells.22,23 In addition, PM-platelet interactions may serve to increase specifically PM synthesis of the adhesive protein thromb~spondin,~~ which mediates platelet-PM cell adhesion via glycoprotein IV." Therefore, in future studies concerning the role of platelets in the contact-mediated activation of the PM 5-lipoxygenase pathway, a potential role of thrombospondin will have to be considered. On the other hand, the stirnulatory effect of platelets could also be brought about by enhancing and/or accelerating effects on contact activation, although such effects have been debated.","
As a test system for further studies on the contact-mediated trigger mechanism, we chose to incubate PM in contactactivated Ca2+-PRP. Under these conditions, the presence of platelets warranted more physiological activation of the intrinsic coagulation than in Ca2+-PPP. Since, in our hands, the determination of cysteinyl-LT serum levels was much For personal use only. on October 22, 2017. by guest www.bloodjournal.org From less critical than that of LTB4, we routinely used the cysteinyl-LT release as a parameter of 5-lipoxygenase activation. However, to show that the results obtained could be extended to PPP and LTB4, in some instances experiments were also performed with Ca2+-PPP and LTB4 was determined.
Initially, we considered components of the intrinsic coagulation cascade assembled on PM membranes" as a potential trigger mechanism. However, we could not gain any evidence for a stimulatoIy effect of factor Xa or factor Va. Contact activation is known to stimulate the intrinsic fibrinolytic pathway in Consequently, when we became aware of the work of Miles et a1 showing that membranes of PM and related monocytoid U937 cells possess binding sites for pla~min(ogen):~-~' we tested the effects of lysine analogs in our system. These compounds are known to inhibit plasmin(ogen) binding to specific receptors on PM membranes, presumably by interaction with the high-affinity lysine binding site of the plasmin(ogen) molecule^.^^^^' Indeed, the rank order of the inhibitory potency of the lysine analogs on cysteinyl-LT release was comparable to that as inhibitors of plasminogen binding to U937 cells. 29 Further experiments demonstrating that plasminogen activators such as urokinase and streptokinase concentrationdependently enhanced the cysteinyl-LT release strengthened the hypothesis that plasmin might be involved in the activation mechanism. Urokinase, as well as streptokinase, led to bell-shaped concentration-response curves, which might be due to proteolytic digestion of the plasmin binding sites. In fact, plasmin is a rather unspecific protease that might, for example, degrade platelet adhesive receptors such as glycoprotein Ib." Although at present the molecular mechanisms leading to the bell-shaped expression of the concentration response curves remain unknown, other investigators have also observed this phenomenon. Both urokinase33 and strept~k i n a s e~~ have been reported to trigger plasmin-mediated effects in citrated plasma, thereby exhibiting bell-shaped concentration-response curves. The profile of the urokinase concentration-response curve with a maximum at 10 IU/mL and a loss of stimulatory activity at 300 IU/mL would suggest that plasma levels of urokinase attained during fibrinolysis (ie, 500 to 2,000 IU/mL)33 should be beyond the concentrations resulting in PM stimulation. By contrast, with a maximum effect at 1 , 0 0 0 IU/mL, streptokinase required much higher concentrations for stimulation of the cysteinyl-LT release. This may be due, at least partially, to complex formation of the activator with pla~min.~' In line with this assumption, we found that the stimulatory effect of plasmin 0.175 Committee on Thrombolytic Agents (CTA) units/mL in HBSS-BSA 0.4% on PM-derived LTB4 formation was inhibited by streptokinase, with an ICso of 1 6 4 IU/mL. Therapeutic dosage of streptokinase 1.5 X lo6 IU/h may well lead to plasma levels of 400 IU/mL:6 which under our in vitro conditions slightly enhanced cysteinyl-LT release already. However, whether this effect may be relevant to clinical situations remains to be established.
The significance of plasmin for the contact-mediated stimulation of the PM 5-lipoxygenase pathway was further demonstrated by experiments with plasmin inhibitors. Both the rather unspecific aprotinin, which in contrast to a,-antiplasmin is even able to inhibit cell-bound plasmin:' as well as the highly specific and physiological plasmin inhibitor, a2-antiplasmin:' concentration-dependently inhibited the contact-mediated 5-lipoxygenase activation to nearly complete blockade.
In our last approach regarding the role of plasmin in the contact-activated 5-lipoxygenase stimulation in PM, we were able to show that monoclonal antibodies directed against miniplasminogen and able to inhibit plasminogen activation" completely blocked the contact-mediated 5-lipoxygenase stimulation in PM incubated in both PRF' or in the absence of platelets in PPP. Thus, by four independent pharmacological approaches using several compounds in three of them, we present convincing evidence that plasmin generated during the process of contact activation plays a critical role for the stimulation of the PM 5-lipoxygenase under these conditions. It is reasonable to assume that the plasmin formation occurs via the contact-activated intrinsic fibrinolytic First, LT production could not be detected when PM were incubated in HBSS-BSA 0.4% under resting conditions. Second, the dextrane sulfate-dependent and therefore contact-mediated fibrinolysis in whole human plasma has been shown to depend on the presence of both factor XI1 and ~rekallikrein:~ as does the contactmediated LT formation. Similarly, a recently described although not fully characterized contact-dependent plasminogen activator, allegedly liable for a substantial part of the contact-dependent intrinsic fibrinolysis, appears to be strictly dependent on activation via factor XI1 and prekallikrein!' Moreover, contact-mediated activation of plasma pro-urokinase, which also appears to be involved in the intrinsic fibrinolytic path~ay,".~' has also been shown to be clearly dependent on the presence of both factor XI1 and prekallikrein.42 Third, addition of aprotinin (6000 KIU/mL) to PMcontaining Ca*+-PRP as early as 3 minutes after contact activation did not reduce LT release over a further 57-minute incubation, while addition at time 0 nearly completely blocked LT release, indicating that the activation occurs during the very early phase of contact activation (unpublished results).
From the experiments discussed so far, it is evident that plasmin plays a pivotal role in the contact-mediated stimulation of the 5-lipoxygenase pathway in PM. In further experiments in which the cells were incubated in HBSS-BSA 0.4%, purified plasmin proved to trigger LT release from PM, yielding a concentration-response curve reminescent of that obtained with plasminogen activators. Similar results were obtained with respect to cysteinyl-LT production when the plasmin stimulation was performed in the presence of washed platelets. The effectiveness of lysine analogs under these conditions indicates that the stimulatory activity of plasmin requires association of the molecule with the PM receptors via its lysine binding sites. It is of considerable interest that plasmin acts relatively selectively on the 5-lipoxygenase pathway, while the release of the two major cyclooxygenase products, TXB2 and PGE2,'* was not significantly affected. It has previously been suggested that release of cyclooxygenase or lipoxygenase metabolites may not necessarily reflect the extent of phospholipase activation For personal use only. on October 22, 2017. by guest www.bloodjournal.org From in Evidence exists, indeed, that within certain limits PM and macrophages might be capable of differential release of cyclooxygenase and lipoxygenase products of arachidonic acid metaboli~m."~~~ Under certain conditions, enhanced LT production might actually be accompanied by reduced PGE, formation.44 These effects might be attributable to compartmentalization of both, the endogenous arachidonic acid liberation, and the 5-lipoxygenase enzyme.I8 Such compartmentalization of phospholipases andlor arachidonic acid metabolizing enzymes could easily explain the relative selectivity of plasmin for the 5-lipoxygenase pathway as found in our study.
Plasmin has previously been shown to affect various cell functions. Thus, low concentrations of plasmin (0.1 to 0.5 CU/mL) appear to inhibit platelet functions at least in part by blocking the mobilization of arachidonic acid from membrane phospholipid p00ls.4~ Higher concentrations of plasmin ( 2 1 .0 CU/mL), on the other hand, trigger platelet activation independent from TXB, formation, but accompanied by intracellular Ca" elevation, phospholipase C activation, and protein pho~phorylation.~~ In this context, peculiar effects of plasmin have been observed on arachidonic acid metabolism. In platelets, as well as in endothelial cells, plasmin seems to cause mobilization of endogenous arachidonic acid, but without significant metabolism to the major cyclooxygenase products formed by these
In endothelial cells, plasmin has also been shown to inhibit tissue-type plasminogen activator release.48 Although in our hands plasmin did not stimulate any LT or prostanoid formation by PMN, these cells apparently do respond to plasmin challenge with cell aggregation and enhanced adherence to endothelial Because little is known so far about potential signal transduction mechanisms in plasmin-mediated effects, further studies are underway to characterize the mechanism leading to PM 5-lipoxygenase activation.
In conclusion, by several independent approaches, our study clearly demonstrates that contact activation of recalcified human plasma triggers activation of the 5-lipoxygenase pathway in PM via plasmin. Since LT formation is a proinflammatory signal, plasmin generated during contact activation may represent a new link between contact activation and the PM component of inflammatory reactions. Contact activation is indeed a common feature in numerous inflammatory diseases, including rheumatoid arthritis,",'* suggesting that the contact-mediated proinflammatory activation of PM might be of considerable pathophysiological importance. Furthermore, these findings indicate a novel pathophysiological role for the contact-activated intrinsic fibrinolytic pathway, which is too weak for efficient fibrinolysis'* but apparently strong enough for proinflammatory activation of PM. 
